Regarding HBM7575, a new drug for the treatment of asthma, the application for clinical trials has been approved by the NMPA.

Bo Medicine-B announced that the new drug clinical trial application for HBM7575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin and an undisclosed target, has been approved by the China National Medical Products Administration for the treatment of asthma. This bispecific antibody was developed in collaboration with Sichuan CrownBio Biotechnology Co., Ltd. Previously, the Phase I clinical study of HBM7575/SKB575 for the treatment of atopic dermatitis has successfully completed the dosing of the first subject.